Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet | Zendy

Chien-Hsin Chang | Zendy; ChingHu Chung | Zendy; Yi-Shu Tu | Zendy; ChengChieh Tsai | Zendy; ChunChieh Hsu | Zendy; HuiChin Peng | Zendy; Yufeng Jane Tseng | Zendy; TurFu Huang | Zendy

Open Access

Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet

Author(s) -

Chien-Hsin Chang,

ChingHu Chung,

Yi-Shu Tu,

ChengChieh Tsai,

ChunChieh Hsu,

HuiChin Peng,

Yufeng Jane Tseng,

TurFu Huang

Publication year - 2017

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.116.308604

Subject(s) - gpvi , chemistry , platelet , platelet activation , platelet membrane glycoprotein , epitope , biochemistry , glycoprotein ib , microbiology and biotechnology , pharmacology , receptor , antibody , immunology , medicine , biology

Currently prescribed antiplatelet drugs have 1 common side effect-an increased risk of hemorrhage and thrombocytopenia. On the contrary, bleeding defects associated with glycoprotein VI (GPVI) expression deficiency are usually slightly prolonged bleeding times. However, GPVI antagonists are lacking in clinic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research